Drugs / acridine carboxamide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00004937 | Oct 1999 → May 2000 | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00004151 | Sep 1999 → Nov 2000 | lung cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | acridine carboxamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004937 ↗ |
| Route | Intravenous | “Patients receive acridine carboxamide IV over 24 hours for 5 days.” NCT00004151 ↗ |